[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an
optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in
subjects with persistent hypertriglyceridemia and high risk for cardiovascular disease.